01 March 2022 : Editorial
Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants
DOI: 10.12659/MSM.936523
Med Sci Monit 2022; 28:e936523